- Dr. Mark Bonyhadi to spearhead
SAB
EDINBURGH, Scotland,
May 18, 2022 /PRNewswire/ -- TC
Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:
TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company
developing platform allogeneic gamma-delta T cell therapies for
cancer and viral indications, announced today announced the
formation of a scientific advisory board (SAB) to advance its
gamma-delta T cell therapy, OmnImmune®, for the treatment of Acute
Myeloid Leukemia (AML).
"We are honored to have these remarkable and accomplished cell
therapeutics and scientific leaders join TC BioPharm's Scientific
Advisory Board," said Bryan Kobel, CEO of TC
BioPharm. "These individuals have made significant
contributions and pioneered breakthroughs in cell therapy research
and therapeutics, and together, they bring a wealth of knowledge
and experience for TC BioPharm, as we work to develop our
proprietary therapies to treat blood cancers and develop our
platform into other oncological areas. We wil continue to expand
our SAB to bring other expertise in cell therapy modalities to
reflect our ongoing R&D efforts as well. TCBP looks forward to
the input of these outstanding individuals as we advance our
platform technology in allogeneic gamma deltas and their
contribution to our ongoing research and development efforts in a
number of project areas."
Members of the TC BioPharm Scientific Advisory include;
Mark Bonyhadi, Ph
D., will lead the SAB. He is a senior advisor to Qiming
Venture Partners USA and former
Vice President of Research at Juno Therapeautics (acquired by
Celgene). Dr. Bonyhadi has more than 30 years of experience
in biopharmaceutical leadership roles in the US, specifically in
the research and development of commercially viable approaches to
take cell and gene therapies, as well as regenerative medicines,
from the lab to the clinic and for subsequent commercial
development. Prior to his role as vice president of Research at
Juno Therapeutics Inc (acquired by Celgene Corporation), he was
Director of Global Business Development for Cell Therapy at
Invitrogen (which merged to become Life Technologies and was
subsequently acquired by Thermo-Fisher) and prior to that, Vice
President ofResearch at Xycte Therapies and a Senior Scientist at
SyStemix, Inc. He was formerly the chair of the Industry Liaison
Committee for the American Society for Gene and Cell
Therapy (2015-2016). He is also the inventor on 11 patents
and an author on 40 publications. He currently is a member of the
scientific advisory board for Akron Biotech and also serves as a
Non-executive Director at TCBP and as a Non-executive
Director at Integra Therapeutics.
Uma Lakshmipathy, Ph D., has two decades of
experience in cell biology, stem cells and translational
research. She is currently the Director of R&D in Science
and Technology and Head of Patheon Translation Services in Pharma
Services Group at Thermo Fisher Scientific. Her work is
focused on developing end-to-end, standardized processes and
analytics for cell therapy and support translational services
destined towards cGMP manufacturing. She has a strong foundation in
development of clinical-grade reagents and processes, viral and
non-viral methods of cell modification and, analytical platforms
for comprehensive cell therapy product characterization. As a
junior faculty at the Stem Cell Institute, University of Minnesota, she was involved in ex
vivo gene repair of disease mutations in adult stem
cells. She has a doctoral degree in Molecular Biophysics from
the Center for Cellular and Molecular Biology in India, postdoctoral experience in DNA double
strand break repair from University of
Minnesota Medical School and has authored several
scientific publications, books and patents.
Erin Adams, Ph D., is the
Joseph Regenstein Professor of Biochemistry and Molecular Biology
at the University of Chicago and an
expert in molecular immunology. She explores the molecular
cues that the human immune system uses to distinguish between
healthy and diseased tissue. Her primary focus is on
unconventional, tissue resident effector cells in the human immune
system including γδ T cells, MR1-restricted and CD1-restricted T
cells. Her laboratory research seeks to understand the role of
these cells types in the immune response process and what signals
regulate their activity in tissue homeostasis and disease. She has
received multiple honors, including being named a Searle Scholar, a
Kavli Fellow and awarded a Cancer Research Foundation Junior
Investigator Award.
About TC BioPharm (Holdings) PLC
TC BioPharm is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of gamma-delta T cell therapies
for the treatment of cancer and viral infections with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC BioPharm uses
an allogeneic approach in both unmodified and CAR modified gamma
delta t-cells to effectively identify, target and eradicate both
liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia and Phase I trial for ImmuniStim in
treatment of Covid patients using the Company's proprietary
allogenic CryoTC technology to provide frozen product to clinics
worldwide. TC BioPharm also maintains a robust pipeline for future
indications in solid tumors and other aggressive viral infections
as well as a significant IP/patent portfolio in the use of CARs
with gamma delta t-cells and owns our manufacturing facility to
maintain cost and product quality controls.
Forward Looking Statements
This press release may
contain statements of a forward-looking nature relating to future
events. These forward-looking statements are subject to the
inherent uncertainties in predicting future results and conditions.
These statements reflect our current beliefs, and a number of
important factors could cause actual results to differ materially
from those expressed in this press release. We undertake no
obligation to revise or update any forward-looking statements,
whether as a result of new information, future events or otherwise.
The reference to the website of TC BioPharm has been provided as a
convenience, and the information contained on such website is not
incorporated by reference into this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-formation-of-scientific-advisory-board-with-renowned-cell-therapy-experts-301550030.html
SOURCE TC BioPharm